Revelation BioSciences
HOME CONTACT
PIPELINE CLINICAL TRIALS
News Presentation CRRT Presentation & Poster Stock Ticker Board Diversity Matrix SEC EDGAR
About Us Board of Directors Management Scientific Advisory Board Core Values
HOME PIPELINE & PROGRAMS PIPELINE CLINICAL TRIALS INVESTORS News Presentation CRRT Presentation & Poster Stock Ticker Board Diversity Matrix SEC EDGAR ABOUT US About Us Board of Directors Management Scientific Advisory Board Core Values CONTACT
Revelation BioSciences

News

Revelation Biosciences Inc. Announces $9.1 Million Common Stock and Series A Financing
James PhillipsJanuary 5, 2021
Revelation Biosciences Inc. Announces the Start of a Phase 1 Clinical Study for REVTx‑99, an Experimental Treatment for Respiratory Viral Infection, Including COVID‑19
James PhillipsNovember 16, 2020
Revelation Biosciences Inc. Appoints Jess Roper to Board of Directors
James PhillipsOctober 15, 2020
Revelation Biosciences Inc. Receives TGA Acknowledgment to Start a Phase 1 Clinical Study of REVTx‑99 an Experimental Treatment for COVID‑19
James PhillipsOctober 7, 2020
Revelation Biosciences Inc. Receives Approval to Start a Phase 1 Clinical Study of REVTx‑99 an Experimental Treatment for COVID‑19
James PhillipsOctober 1, 2020
Newer
 
 

Subscribe

Sign up with your email address to receive news and updates.

Thank you!
 
Terms of UsePrivacy

© 2025 Revelation BioSciences